Esperion Therapeutics Cash Flow - Quarterly (NASDAQ:ESPR)

Add to My Stocks
$47.71 $1.09 (2.23%) ESPR stock closing price Jul 21, 2017 (Closing)

The Esperion Therapeutics cash flow statement is one of the three reports that the company generates every quarter. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Esperion Therapeutics profits and Esperion Therapeutics debt. Items like capital purchases, bank loan payments etc. which have a direct impact on the cash position of a company come out through the statemement of cash flows and help an investor who undertakes the Esperion Therapeutics stock analysis. Esperion Therapeutics generated $-34.31M cash from operating activities in 2017-Q1. The cash from operating activities for Esperion Therapeutics is $-34.31MĀ for 2017-Q1, which saw an increase of -28.12% from previous quarter. View details of Esperion Therapeutics cash flows for latest & last 40 quarters.

show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4
Esperion Therapeutics Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow0.22M1.31M0.99M0.64M0.33M0.94M0.61M0.32M0.1M0.39M
Net Increase (Decrease) in Assets Liabilities1.85M9.98M1.23M2.18M-0.1M-2.08M-1.99M0.69M0.02M0.25M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net4.15M15.95M12.38M8.67M4.55M12.77M8.33M4.97M2.07M3.71M
Esperion Therapeutics Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.01M-0.09M-0.01M-0.01M--0.3M-0.08M-0.01M-0.01M-0.86M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments16.18M10.21M2.37M-10.69M-29.96M-159.76M-165.32M-128.13M-57.54M-35.73M
Other Cash Inflow (Outflow) from Investment Activities----------
Esperion Therapeutics Net Cash from (used by) Invesment Activities
Issuance (Purchase) of Equity Shares0.26M0.04M0.04M0.03M0.02M191.16M191.15M190.78M190.41M92.28M
Issuance (Repayment) of Debt Securities-0.41M-1.6M-1.19M-0.78M-0.39M-0.63M-0.25M--4.83M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Esperion Therapeutics Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Esperion Therapeutics Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year77.33M85.03M56.53M6.51M1.57M3.41M----
Cash & Equivalents at Year End19.86M38.16M47.14M48.76M37.2M77.33M80.82M129.78M208.64M85.03M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Cash flow for another ticker

While Esperion Therapeutics stock price history provides the price history of a stock, Esperion Therapeutics stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:
  • Esperion Therapeutics had a Net Change in Cash and Cash Equivalents of $-18.29M for the latest quarter 2017-Q1. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Esperion Therapeutics stock price , albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • The cash generated from the core business or operations was negative at $-34.31M for Esperion Therapeutics in the latest quarter. For an internet company, this would include all those activities which are involved in eventually selling advertisement space on its website or any online service.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc. , and was $-34.31M for ESPR in last quarter report.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $-0.15M for Esperion Therapeutics.